Background: The relative efficacy of interventions for primary prevention of anthracycline-associated cardiotoxicity is unknown.
Introduction
Anthracyclines form of the cornerstone of many chemotherapeutic regimens but increase the risk of cardiomyopathy and heart failure [1] . Prior studies have suggested that dexrazoxane, angiotensin antagonists (AA's), beta-blockers (BB's), and statins may reduce this risk [2] . However, there is little data on the efficacy of these treatments relative to each other and little guidance for clinicians or researchers to prioritize one agent over another.
Here, we report a systematic review of randomized controlled trials (RCT's) of primary prevention of anthracycline-associated cardiotoxicity in adult cancer patients. We carried out a network meta-analysis to facilitate indirect comparisons of therapies that had not been tested against each other. We employed Bayesian methods to quantify the uncertainty associated with the conclusions drawn from the available data and present it in an intuitive manner [3, 4] .
Methods

Search strategy and data extraction
A comprehensive search strategy was conducted by an information specialist in the following databases through the OvidSP platform: Medline (1946 to November Week 3 2014), Medline In-Process and Other NonIndexed Citations (13 January 2015) , EMBASE (1974 EMBASE ( -2015 09 January ), Cochrane Database of Systematic Reviews (2005-November 2014), and Cochrane Central Register of Controlled Trials (December 2014) without language or date restrictions. We sought RCTs and systematic reviews, which examined the efficacy of pharmacologic interventions in reducing cardiotoxicity among adult patients treated with an anthracyclinecontaining regimen for solid or haematologic malignancies in the adjuvant or metastatic disease setting. We excluded pediatric studies. The search strategy was done in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) recommendations. Reference lists of articles chosen for detailed review, as well as review articles and meta-analyses published within the past 5 years, were also handsearched. The detailed search strategy is provided in the supplementary material (available at Annals of Oncology online).
The main comparison was any pharmacologic agent, compared with another pharmacologic agent or non-treatment control. The primary outcome of was the development of cardiotoxicity. We accepted three outcome definitions: (i) a composite of congestive heart failure (CHF) or a clinically relevant decline in left ventricular ejection fraction (LVEF), utilizing the cut-off used in individual studies, (ii) a clinically relevant decline in LVEF alone, and (iii) CHF (regardless of availability of data on LVEF). We utilized hierarchy-based selection with a preference for the more sensitive option when more than one outcome was available, i.e. outcome definition (i) was preferred over (ii) and outcome definition (ii) was preferred over (iii). Each of these outcomes was also assessed separately. To better understand net clinical benefit, we included the following secondary safety outcomes a priori to encompass potential adverse effects: malignancy response rate, death, hemodynamic adverse events, neutropenia, and thrombocytopenia.
The citations were de-duplicated, after which one author (HAQ) reviewed them and identified articles for inclusion in the meta-analysis. The data were extracted by two authors (HAQ and GO) and discrepancies resolved by consensus. angiotensin converting enzyme (ACE)-inhibitors and angiotensin receptor blockers (ARBs) were treated as one group due to perceived interchangeability and similar mechanisms of action (henceforth referred to as AA's). The number of patients in each treatment arm who experienced each outcome of interest and the number analyzed were extracted, using intention-to-treat analyses where available. We also collected data on patient demographics, malignancy, and the mean or median doxorubicin-equivalent dose of anthracycline. The risk of bias of each study was assessed by a single author (HAQ) using the Cochrane tool [5] and results summarized pictorially using Review Manager software package, Version 5.3 [6] .
Statistical analysis
For each outcome, a Bayesian random effects mixed treatment comparison model [3] was fitted in OpenBUGS [7] . A random effects model was chosen to account for heterogeneity in patients, malignancies and interventions evaluated. The event count within each arm was modeled as arising from a binomial distribution. Our outcome measure was the odds ratios (OR) with active treatment relative to control. Given modest event numbers, we used a moderately informative prior distribution for the natural logarithms of the OR for average treatment effects relative to control; they were normally distributed with a common mean of 0, and a standard deviation putting 95% probability on true OR of 0.1-10. For the prior on the between-study heterogeneity parameter, we used the predictive distribution suggested by Turner et al. for studies evaluating pharmacologic agents versus control with a major morbidity outcome [4] . This was a log normal distribution with a mean value of À3.71 for the logarithm of the variance and 1.74 for its standard deviation. Noninformative prior distributions were used for other model parameters.
The model was run with three chains starting from randomly chosen initial values, using Markov Chain Monte Carlo simulation to generate samples from posterior distributions for the model parameters. Convergence was established by inspection of the trace "history" feature to establish homogenous parameter estimates and through the BrooksGelman-Rubin diagnostic statistic (see supplementary Figure S1 , available at Annals of Oncology online). Once convergence was established, 100 000 further iterations from each chain generated samples for inference, which were exported to the R statistical software package [8] for further computation. We calculated posterior means, medians and 95% central credible intervals (CrI) for the ORs comparing treatment to control. Finally, we estimated the probability that each treatment was most effective by the proportion of all posterior samples in which the treatment was associated with the lowest OR. We calculated numbers needed to treat (NNT) based on pooled event rates in control arms (details in sup plementary material available at Annals of Oncology online). We subsequently conducted a meta-regression analysis evaluating the association of mean age, percentage of males, and the mean or median anthracycline exposure (binary variable denoting whether !300 mg/m 2 ) with the OR. The results are presented in accordance with recommendations on reporting Bayesian analyses of clinical studies [9] .
Sensitivity analyses
We conducted a sensitivity analysis using a wider prior distribution for the between-study heterogeneity with a quadrupling of the mean variance (mean value of À2.33 for the log-normal distribution). Due to concerns about a markedly different set of results in one study [10] relative to others studies investigating the same agents (detailed in the "discussion section), we also carried out a post hoc sensitivity analysis excluding it from the meta-analysis examining the primary outcome.
Results
Studies and patients
The PRISMA flow diagram (supplementary Figure S2 , available at Annals of Oncology online) illustrates that of 32 articles retrieved for detailed review, 16 were included in the metaanalysis [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] . Figure 1 shows the network of studies used, which encompassed 1918 patients. Notable baseline characteristics are summarized in supplementary Table S1 (available at Annals of Oncology online). The mean age was 44 years and 14% were male. Patients were divided evenly between control (n ¼ 948) arms and intervention arms (n ¼ 970). In intervention groups, 666 were treated with dexrazoxane (eight studies), 124 with AA's (three studies), 67 with BB's (two studies), 20 with statins (one study), 42 patients with both AA's and BB's (one study), 24 with N-acetyl cysteine (one study), 10 with co-enzyme Q10 (one study), and 14 with prenylamine (one study). Only two studies directly compared more than one intervention: one study evaluated AA's, BB's and control, while the other compared dexrazoxane, Co-enzyme Q10, and control [13, 21] .
The mean of the reported central estimates of anthracycline dose was 389 mg/m 2 . Among studies with malignancy diagnosis data, 66% had breast cancer and 19% had haematologic malignancies. Over 975 of patients in whom dexrazoxane was studied had advanced disease or failed to respond to first-line chemotherapy. We could not reliably estimate the proportion of patients treated with curative versus palliative intent for other agents. A summary of the risk of bias assessment is illustrated in the supple mentary Figure S3 (available at Annals of Oncology online), demonstrating that the most common threat to validity was lack of allocation concealment and double-blinding. The method of blinding was also inconsistently reported.
Total cardiotoxicity events
The measures of cardiotoxicity in study arms are listed in the sup plementary Table S2 (available at Annals of Oncology online). There were 422 cardiotoxicity events among 1918 assessable patients (overall incidence 22%; control group incidence 34%). As summarized in Table 1 , dexrazoxane-reduced cardiotoxicity with a median pooled OR of 0.26 relative to control (95% [CrI] 0.11 -0.73). This corresponded to a NNT of 4.5 (see supplementary ma terial for NNT at other event rates, available at Annals of Oncology online). The results were consistent, with most OR's between 0.22 and 0.26 except for two studies with OR's of 0.09 and 0.37. No other agent was demonstrably better than control as the CrIs for the corresponding pooled OR all crossed one. Among the 9 treatment strategies studied (including control), dexrazoxane had the highest probability of being most effective, being associated with the lowest OR in 33% of simulations drawing from the posterior probability distribution. The sensitivity analysis using a wider prior distribution for the between-study heterogeneity yielded similar results, with wider CrIs. Dexrazoxane remained the most effective treatment (32% probability), and was associated with a median OR of 0.27 (95% CrI 0.11-0.81) relative to control.
There was more inconsistency among studies evaluating AA's. The study by Georgakopoulos et al. [10] reported an OR of 7.3 for cardiotoxicity with AA relative to control, while the study by Cardinale et al. [14] reported an OR of zero. In the sensitivity analysis excluding the Georgakopoulos study, AA's were the most effective agent for the prevention of cardiotoxicity, with a pooled median OR of 0.06 relative to control (95% CrI 0.01 -0.24). AA's were also likeliest to be most protective, with an 84% probability of being ranked best in simulations drawing from this posterior probability distribution. The median OR for dexrazoxane relative to placebo remained unchanged at 0.24 (95% CrI 0.16-0.36).
Secondary efficacy outcomes
CHF was reported in trials evaluating dexrazoxane, AA's, BB's, prenylamine, and N-acetyl cysteine. There were 123 CHF events reported among 1690 patients that were assessed, corresponding to an overall incidence of 7.2% (control group incidence 13%). Dexrazoxane was associated with the largest risk reduction, with a pooled OR of 0.12 (95% CrI 0.06 -0.23) relative to control (OR range 0.07 -0.46). This corresponded to a NNT of 9.2 (see supple mentary Material for NNT at other event rates, available at Annals of Oncology online). AA's were also associated with a pooled OR of 0.18 (95% CrI 0.06 -0.51), corresponding to a NNT of 9.9. Other treatments were not demonstrably better than Figure 1 . Network of studies included in the meta-analysis of all cardiotoxicity events (clinical or subclinical). Circles connected by a line indicate treatment arms that have been directly compared with each other.
control, as summarized in Table 1 . Dexrazoxane had the highest probability (58%) of being most effective for CHF prevention.
Ten studies reported declines in LVEF [11-15, 17, 20-23] : 4 studied dexrazoxane [11, 15, 17, 20] , one studied dexrazoxane and co-enzyme Q10 [21] , 2 assessed AA's [14, 22] , one BB's [23] , one statins [12] , and one assessed a combination of ACE-inhibitors and BB's [13] . There was notable variation in the definition of a clinically relevant LVEF decline, as detailed in the supplementary material (available at Annals of Oncology online). Recent echocardiography-based studies [12] [13] [14] 23] generally defined it as a decrease to a final value <50%, with one study [22] using a <55% cut-off. Two studies [14, 26] required a >10% absolute decrease from baseline. Older studies [15, 17, 20] utilizing multigated acquisition (MUGA) scans defined it as a decrease to a final value of 45% or below, or an absolute decline by !20% from baseline. There were 125 events meeting these definitions of cardiotoxicity among 813 evaluated patients (incidence 15.4%). These data suggested a credible protective effect for AA's (OR 0.06; 95% CrI 0.01 -0.29), which were the most effective intervention in 85% of simulations, as well as for dexrazoxane (OR 0.17 95% CrI 0.09 -0.39).
Safety outcomes
The pre-specified safety outcomes were inconsistently and rarely reported. Malignancy response rates were reported in 8 trials that examined dexrazoxane (5 trials, 1002 patients), AA's (2 trials, 163 patients), and N-acetylcysteine (1 trial, 54 patients). There were 560 non-responders out of 1219 patients that were assessed. None of the agents appeared to modify this risk. For dexrazoxane, the pooled OR for non-response was 1.21, with a 95% CrI of 0.89-1.61. The corresponding OR was 0.68 (95% CrI 0.19-2.34) for AA's and 0.65 (95% CrI 0.23-1.96) for N-acetylcysteine.
In addition, all-cause death was reported in seven studies: four evaluated dexrazoxane and one each evaluated AA's, BB's, and the combination of the latter two agents. The impact of these agents was similar to control with a median OR of 0.89 (95% CrI 0.53-1.49) for dexrazoxane, 0.74 (95% CrI 0.16-3.51) for AA's, 0.42 (95% CrI 0.08-1.85) for BB's, and 0.42 for the combination (95% CrI 0.13-1.41). Fewer data were reported for adverse hemodynamic or hematologic adverse events, suggesting no substantial difference from control (see supplementary Table S3 , available at Annals of Oncology online).
Inter-study heterogeneity
The median value for the standard deviation around the logarithm of the OR between studies was 1.06, corresponding to extreme heterogeneity. With this degree of between-study heterogeneity, if we consider two studies estimating the same treatment effect, the median ratio of the larger OR to the smaller OR is 2.75. This markedly decreased in the sensitivity analysis excluding the Georgakopoulos study, where the posterior distribution yielded a median value of 0.47. This indicates moderate heterogeneity (i.e. the OR ratio described earlier has a median of 1.56). Corresponding measures in the analyses that restricted the outcome to CHF or declines in LVEF were comparable and also suggested a moderate degree of between-study heterogeneity. Meta-regression analyses using available data demonstrated that the mean age of study participants, the proportion of male patients, and the central measure of anthracycline exposure were not credibly associated with treatment effect (see supplementary  Table S4 , available at Annals of Oncology online).
Discussion
This network meta-analysis facilitated indirect comparisons of pharmacotherapies for primary prevention of anthracyclineassociated cardiotoxicity. Our results suggest that dexrazoxane and AA's are most likely to be effective at preventing cardiotoxicity. The data supporting dexrazoxane was of moderate quality, being mostly derived from patients with advanced cancer treated >20 years ago. On the other hand, the data supporting AA's was of low quality, being highly sensitive to inclusion of data published in a research letter by Georgakopoulos et al. However, the strong benefit for AA's in analyses that excluded this data was driven by Cardinale et al., who randomized 56 patients to enalapril and 58 to control. Thus, future studies are highly likely have an important impact on our understanding the utility of this promising intervention.
No other agent was demonstrably better than control, but this was based on limited data. There were even less data on The ORs are reported for the agent evaluated relative to control.
treatment-related adverse events. The number of patients included in the evaluation of most therapies was small and the data quite heterogeneous, leading to wide credible intervals for all estimates. Thus, data are of low quality, and the most important conclusion from our analysis is the need for further studies to more precisely quantify effect estimates, particularly for AA's. Four relevant studies could not be included in the meta-analysis because they only reported continuous LVEF data. Nakamae et al. demonstrated no significant change in LVEF among anthracycline-treated patients receiving valsartan compared with usual care [27] . Two other studies suggested that prophylactic beta-blockers lead to a significantly higher LVEF after anthracycline exposure relative to control [28, 29] . Finally, the Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA) trial showed that candesartan maintained LVEF stability with adjuvant anthracyclines and compared with a significant decline in placebo-and metoprolol-treated patients [30] .
This meta-analysis has several limitations. Any biases and inaccuracies within individual studies would be transmitted into our analysis. Also, many studies used much higher doses of anthracyclines than contemporary practice, particularly in the adjuvant setting. Two studies were published as research letters and may have not gone through the same rigor of peer review as a research article [10, 12] . We should also note that the United States Food and Drug Administration and the European Medicinal Agency limit their approval for the use of dexrazoxane to patients treated with high dose anthracyclines (>300 mg/m 2 of doxorubicin) for metastatic disease and not in the adjuvant setting.
Conclusion
This network meta-analysis suggests that dexrazoxane is most likely to be effective at reducing clinical and subclinical cardiotoxicity events. AA's are also likely to be effective if we exclude the data from a single aberrant study. The meta-analysis highlights the need for larger studies directly comparing active treatments to each other. It also suggests that future studies on primary prevention of cardiotoxicity should prioritize AA's and dexrazoxane in the adjuvant setting. Clinically relevant safety outcomes should also be more systematically measured to allow more informed decision-making.
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